Publications by authors named "Dale E Shuster"

Claim this Profile
L
Long-term efficacy and safety of pexidartinib in patients with tenosynovial giant cell tumor: final results of the ENLIVEN study.
Andrew J Wagner, William D Tap, Sebastian Bauer, Jean-Yves Blay, Jayesh Desai, Dale E Shuster

Oncologist· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dosing Recommendation Based on the Effects of Different Meal Types on Pexidartinib Pharmacokinetics in Healthy Subjects: Implementation of Model-informed Drug Development Strategy.
Hamim Zahir, Ophelia Yin, Ching Hsu, Andrew J Wagner, Jason Jiang, Dale E Shuster

Clin Pharmacol Drug Dev· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pexidartinib Long-Term Hepatic Safety Profile in Patients with Tenosynovial Giant Cell Tumors.
James H Lewis, Hans Gelderblom, Michiel van de Sande, Silvia Stacchiotti, John H Healey, Dale E Shuster

Oncologist· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term outcomes of pexidartinib in tenosynovial giant cell tumors.
Hans Gelderblom, Andrew J Wagner, William D Tap, Emanuela Palmerini, Zev A Wainberg, Dale E Shuster

Cancer· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial.
William D Tap, Hans Gelderblom, Emanuela Palmerini, Jayesh Desai, Sebastian Bauer, Dale E Shuster

Lancet· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine.
Javier Cortes, Linda Vahdat, Joanne L Blum, Chris Twelves, Mario Campone, Dale E Shuster

J Clin Oncol· September 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The odyssey of marine pharmaceuticals: a current pipeline perspective.
Alejandro M S Mayer, Keith B Glaser, Carmen Cuevas, Robert S Jacobs, William Kem, Dale E Shuster

Trends Pharmacol Sci· June 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane.
Linda T Vahdat, Brian Pruitt, Carol J Fabian, Ragene R Rivera, David A Smith, Dale E Shuster

J Clin Oncol· June 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I study of eribulin mesylate administered once every 21 days in patients with advanced solid tumors.
Antoinette R Tan, Eric H Rubin, Diana C Walton, Dale E Shuster, Y Nancy Wong

Clin Cancer Res· June 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced solid malignancies.
Sanjay Goel, Alain C Mita, Monica Mita, Eric K Rowinsky, Quincy S Chu, Dale E Shuster

Clin Cancer Res· June 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis